June I 2025

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

Explore the complexities of non-clear cell renal cell carcinoma, its treatment challenges, and promising immunotherapy advancements for better patient outcomes.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

Explore the role of consolidative thoracic radiotherapy in enhancing survival for extensive-stage small cell lung cancer post-chemoimmunotherapy.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations and MET overexpression.

Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.